Last update May 23, 2019
Precursor of Penciclovir which is used for treatment of Herpes zoster infections and genital and mucocutaneous Herpes simplex (Novartis 2014, AEMPS 2010).
Oral administration in 2 - 3 daily doses.
At latest update, relevant published data on excretion into breast milk were not found.
Its pharmacokinetic data (low molecular weight and low percentage of plasma protein binding) makes it likely that significant amounts will pass into breast milk, although its large volume of distribution (Gill 1996) would make it difficult.
Its side effects are rare and mild (Mubareka 2010, Mactal 2001).
Possibly has low risk during breastfeeding because of having similar pharmacokinetics and side effects than other antivirals of the same family that are considered compatible with breastfeeding.
Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable (Mactal 2001), especially during the neonatal period and in cases of prematurity
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM